Krishna Institute of Medical Sciences Ltd Share Price

Overview

Krishna Institute of Medical Sciences Ltd share price is currently ₹776.25, up by ₹22.85 (3.03%) from its previous closing price of ₹753.40. The share price has gained 17.89% over the past month and gained 18.96% over the past year. The stock's 52-week low and high are ₹569.07 and ₹843.75, respectively. Krishna Institute of Medical Sciences Ltd has a market capitalisation of ₹ 32,300.60 Cr. The share price was last updated on 20 Nov 2026, 01:04 PM IST.

Krishna Institute of Medical Sciences Ltd
Krishna Institute of Medical Sciences Ltd
KIMS
 ₹0.00
 ₹22.85
3.03%
Healthcare
 ₹0.00(%)1D

Updated: 20 Nov 2026, 01:04:15 pm IST

Market Data

Open Price

 ₹755.77

Prev. Close

 ₹753.40
 ₹746.27

Day Low

 ₹783.56

Day High

 ₹569.07

52 Week Low

 ₹843.75

52 Week High

HealthcareHospital & Healthcare Services
CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

148.71

Sector PE

45.96

PB Ratio

13.81

Sector PB

6.03

EPS

5.22

Dividend Yield

0.00

Today's Volume

600.893 K

5 Day Avg. Volume

480.506 K

PEG Ratio

-4.00

Market Cap.

₹ 32,300.60 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
Stock Split2:10
13-Sep-202413-Sep-2024

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
HDFC Small Cap Fund - Regular Plan - Growth1.11 Cr
1.11 Cr
no change
SBI Small Cap Fund - Regular Plan - Growth1.10 Cr
1.10 Cr
no change
Axis Small Cap Fund - Regular Plan - Growth1.01 Cr
94.96 Lac
(6.26%)
Kotak Small Cap Fund - Growth84.54 Lac
84.54 Lac
no change
Invesco India Smallcap Fund - Regular Plan - Growth73.83 Lac
74.33 Lac
(0.68%)

About Krishna Institute of Medical Sciences Ltd 👋

Krishna Institute of Medical Sciences Ltd is an India-based company, which is primarily engaged in the business of rendering medical and healthcare services. The Company's departments include accident, Alzheimer center, andrology and Male infertility center, pediatric obesity, pediatric oncology and hematology center, pediatric orthopedics and rheumatology, pediatric renal centre, pediatric surgical centre, female urology centre, fertility centre, gastrointestinal oncology, general surgery, heart wellness center, hepatobiliary surgery center, and others. Its medical technologies include 4-Arm HD da Vinci Robotic Surgical System, O-Arm Scanner, Novalis Tx Linear Accelerator, 3 Tesla MRI, 4D Scan for pregnancy, EBUS, Spy Glass, Mako Robotic for Knee Replacement, Impella, and others. The Company's institutes include the Institute of Cardiac Sciences, Institute of Dental Science, Institute of Gastroenterology & Hepatology, Institute of Heart & Lung Transplantation, among others.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Pyrifera Investment Advisors

Pyrifera Investment Advisors

14 Nov • 2:18 PM · SEBI-Registered Analyst

KIMS secures 10-year O&M deal for 250-bed Kerala hospital

KIMS subsidiary KSPL signed a 10-year operations and management agreement for the 250-bed Westfort Hi-Tech Hospital in Kerala. The deal guarantees a monthly fee of ₹50 lakh or 9% of net revenue, commencing November 4, 2026. The agreement expands KIMS's footprint in Kerala without heavy capital expenditure, leveraging its established management expertise. This matters because it generates predictable, annuity-like revenue while scaling the brand in a high-potential southern market. I am watching the Q3 FY27 earnings call in January 2027 for the exact revenue realization from this 9% net revenue share and the sequential bed occupancy metrics at the Thrissur facility. The market typically views hospital O&M contracts as low-margin, administrative overlays. What the consensus misses is the structural operating leverage this specific asset-light expansion enables. Step one: a 10-year term with a 5-year extension option provides long-duration revenue visibility without the balance sheet drag of greenfield capex. Step two: the ₹50 lakh monthly floor or 9% revenue share perfectly aligns KIMS's incentives with hospital throughput, capturing upside as occupancy scales. Step three: entering Kerala via an established 250-bed facility bypasses the multi-year regulatory and brand-building hurdles of a new greenfield hospital. The market misprices this as a minor regional contract, ignoring it is a highly capital-efficient wedge into a new geographic market. Accumulate for long-term asset-light margin expansion. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice. KIMS

See More
Clovek Advisory

Clovek Advisory

5 Nov • 11:38 AM · SEBI-Registered Analyst

KIMS reports Q2 FY27 growth with 14.0% QoQ revenue increase

KIMS Capex intensity: cash flows from investing are strongly negative (–₹1,452 Cr vs –₹1,116 Cr prior), signalling heavy near-term investment and cash absorption for new hospitals/CWIP (CWIP ₹606 Cr). Asset base: fixed assets ~₹5,710 Cr with CWIP shows an asset-heavy expansion; incremental beds materially increase capacity and future revenue potential once utilization ramps. Profitability signal: ROCE has declined (latest ~10% from ~15%), indicating current returns are under pressure — new capacity must achieve strong utilisation to restore returns. Valuation sensitivity: market cap ~₹31,104 Cr and high P/E (~149) imply the stock already prices future growth; execution shortfalls or slow ramp-up would hurt investor returns. High-value services: addition of oncology, NICU and mother/child blocks increases potential ARPOB and margin mix if case mix and utilisation rise as expected.

See More
Harika Enjamuri

Harika Enjamuri

2 Nov • 10:41 AM · SEBI-Registered Analyst

KIMS doubles Anantapur hospital capacity to 500 beds

Krishna Institute of Medical Sciences Limited has doubled the capacity of KIMS Saveera Hospital in Anantapur, Andhra Pradesh, from 250 to 500 beds. The expansion adds specialised cancer care and maternal and child healthcare facilities. The expanded hospital includes an oncology block equipped with a high-definition linear accelerator, PET-CT scanning and brachytherapy facilities. A dedicated mother and child block with specialised neonatal intensive care facilities has also been added. The expansion is aimed at improving access to advanced healthcare across the Rayalaseema region. It also increases KIMS' capacity to serve patients requiring specialised treatment, including cancer care and neonatal services. This development follows KIMS' recent agreement to manage Trust Multi Speciality Hospital in Kakinada, which has an installed capacity of 183 beds. Under the five-year agreement, KIMS will receive 9% of the hospital's net revenue, with an option to extend the arrangement for another five years. My view: The key factor is whether the additional beds translate into higher occupancy and better revenue per patient. Oncology and other specialised services can support a broader treatment mix, but the financial benefit will depend on patient volumes, operating costs and the time needed to utilise the expanded capacity. The Kakinada agreement also offers a way to expand operations without relying entirely on new hospital construction, although its contribution will depend on the revenue generated. KIMS shares trading today at ₹713.80 on the NSE, up 1.71%. I would watch upcoming quarterly results for hospital occupancy, revenue growth and operating margins to assess whether this capacity expansion is translating into stronger financial performance. My stance: Operationally positive, but sustained revenue growth and margin improvement are needed to confirm the financial impact. KIMS Disclaimer: This post is for informational purposes only.

See More
Sasi Kumar

Sasi Kumar

20 Oct • 1:10 PM · SEBI-Registered Analyst

Healthcare Stocks for a Long-Term Watchlist

Healthcare demand does not depend entirely on how the stock market performs. People need medical treatment in good and bad economic conditions. Rising incomes, wider insurance coverage and higher spending on healthcare can support the sector over time. Here are 7 listed healthcare companies to study for a long-term watchlist: • Apollo Hospitals • Max Healthcare • Fortis Healthcare • Narayana Health • KIMS • Rainbow Children’s Medicare • Aster DM Healthcare Before investing, compare each company’s valuation, revenue growth, debt, margins and expansion plans. A growing sector does not mean every stock is available at the right price. Not a buy/sell recommendation. For educational purposes only.

See More
TrueNorth Capital

TrueNorth Capital

11 Oct • 2:53 PM · SEBI-Registered Analyst

Krishna Institute of Medical Sciences expands home clusters

Krishna Institute of Medical Sciences [ KIMS ] announced strategic investments in four hospitals within existing business clusters, alongside an ongoing expansion plan to more than double total bed capacity to over 9,600 beds. The announcement covers controlling stake acquisitions in Guntur and Kakinada in Andhra Pradesh, alongside equity investments in Kompally in Telangana and Sangli in Maharashtra. Total bed capacity reached 7,459 beds in the first quarter of fiscal 2027, up from 3,975 beds in fiscal 2024. This matters because aggressive greenfield and multi-state expansions have put pressure on financial health. EBITDA margins dropped from 26 percent in fiscal 2024 to 20.1 percent in the first quarter of fiscal 2027, while debt climbed significantly, prompting a Rs 1,500 crore qualified institutional placement to repay borrowings. The market headline focuses on expansion, but misses the strategic nuance that these specific transactions target familiar territory. KIMS already shares operations and maintenance partnerships with the Guntur and Sangli units, while the Kakinada asset is profitable. By focusing on core clusters where regional dominance is established, integration friction and cash burn should remain lower than unproven greenfield rollouts. Investors must monitor whether margin compression stabilizes as bed utilization improves. Watch debt levels and return on capital employed closely as new units scale up. View: Neutral to positive on cluster consolidation execution, pending margin recovery.

See More
Pyrifera Investment Advisors

Pyrifera Investment Advisors

6 Oct • 10:18 PM · SEBI-Registered Analyst

KIMS buys 6% equity in Sangli hospital for ₹15 cr

KIMS is acquiring a 6% equity stake in Ushahkal Abhinav Specialty Hospital for ₹15 crore by October 31, 2026. This shifts the company from a pure management-fee model to direct equity ownership in the 316-bed facility. The transaction converts a prior 9% net revenue O&M agreement into a formal equity partnership. This matters because it de-risks regional expansion by testing operational viability first before committing balance sheet capital, complementing KIMS's concurrent 51% acquisition of Guntur-based Insignia Healthcare. I am watching the October 31, 2026 integration completion and the Q3 FY27 earnings call for the specific EBITDA contribution from this newly consolidated Sangli medical cluster. The market often views small, single-hospital equity stakes as negligible to a large-cap player's valuation. What the consensus misses is the structural advantage of this specific "O&M to equity" playbook. By initially running the facility on a 9% revenue-share model, KIMS validated the cash flows and operational metrics without upfront capex risk. Now, deploying just ₹15 crore to lock in a 6% equity stake secures a permanent foothold in the high-growth Sangli-Miraj-Kupwad cluster. This is not merely an asset acquisition; it is a highly capital-efficient moat-building exercise that creates a regional network effect alongside KIMS's Nagpur and Nashik facilities, driving long-term patient referrals and superior return on capital employed (ROCE). Accumulate for long-term regional consolidation and capital efficiency. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice. KIMS

See More

News & Events

Frequently Asked Questions

What is the share price of Krishna Institute of Medical Sciences Ltd?

What is the market cap of Krishna Institute of Medical Sciences Ltd?

Should I buy Krishna Institute of Medical Sciences Ltd stock now?

What is the 52 week high and low of Krishna Institute of Medical Sciences Ltd?

Is the Krishna Institute of Medical Sciences Ltd stock good to buy?

Is Krishna Institute of Medical Sciences Ltd a good buy for the long term?

Is Krishna Institute of Medical Sciences Ltd overvalued or undervalued?

What is the PE and PB ratio of Krishna Institute of Medical Sciences Ltd?

Start Now